Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|November 15, 2016
SCRS Welcomes GlaxoSmithKline as a Global Impact Partner
Advertisement
Ellicott City, MD – The Society for Clinical Research Sites (SCRS) announces GSK as a Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
GSK was a finalist for the 2016 SCRS Eagle Award honoring clinical research sponsors and CROs which are highly ranked by sites.
“GSK’s commitment to the sites through their collaboration with SCRS is a strong signal of the value they see in sites having a unified voice and wanting to be part of that dialogue and community,” said SCRS President, Christine Pierre. “We look forward to ongoing collaboration with GSK to ensure they benefit from the value of the SCRS community as well, which ultimately will strengthen the sponsor and site partnership.”
Anne Marie Inglis, Head of US Clinical Operations, GSK comments “We believe the support and continued development of investigational sites is a key component in clinical trial success. As the individuals actually working daily with clinical trial subjects, investigational sites offer keen insight into improving the clinical trial experience. The SCRS network offers GSK an opportunity to build stronger relationships with the site community and work together to enhance the conduct of clinical trials.”
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit
About GlaxoSmithKline
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
Where AI Governance in Clinical Development Falls Short
5